Mavyret: A Phase 3b, single arm, open-label, multicenter study to evaluate the safety and to demonstrate the non-inferiority of the sustained virologic response 12 weeks post dosing (SVR12) rates of 8 weeks of treatment with the glecaprevir (GLE)/pibrentasvir (PIB) combination regimen to the historical SVR12 rate of 12 weeks of treatment with the GLE/PIB in treatment-naïve adults with chronic HCV GT 1, 2, 4, 5, or 6 infection and compensated cirrhosis.
This is an observational study to find out the ‘real world’ effectiveness (cure) of AbbVie’s Viekira Pak (with and without ribavirin) in genotype 1 and 4 patients. This includes treatment-naïve and treatment experienced patients. AbbVie’s drug combinations are approved by the Food and Drug Administration (FDA) to treat hepatitis C genotype 1 (cure rates = 95 to 100%) and genotype 4 (cure rates = 91 to 100%).
Israel: Real World Evidence of the Effectiveness of Paritaprevir/r – Ombitasvir, ± Dasabuvir, ± Ribavirin and Patient Support Program in Patients With Chronic Hepatitis C (CITRINE)